Shares of the drugmaker jumped about 8% in Thursday trading after easily beating earnings expectations.
Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Revenue in the second quarter jumped 36% year over year to $11.3 billion, easily topping expectations of $9.92 billion, according to estimates compiled by LSEG. Adjusted earnings per share in the three months ended June 30 totaled $3.92, far outpacing the $2.60 estimate, LSEG data showed.
Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock.
Jim Cramer Investment Strategy Markets Breaking News: Markets Eli Lilly And Co Merck & Co Inc Pfizer Inc Biogen Inc Novo Nordisk A/S Roche Holding AG Viking Therapeutics Inc Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from RocheNovo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche’s latest obesity drug candidate.
Read more »
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from RocheNovo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate.
Read more »
Stocks making the biggest moves midday: Eli Lilly, Under Armour, Warner Bros. Discovery and moreThese are the stocks posting the largest moves in midday trading.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterEli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker. Lilly also hiked its forecast for the year well beyond Wall Street expectations as newer drugs like Zepbound built momentum.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterMounjaro sales more than tripled in the quarter to nearly $3.1 billion. Zepbound, which is made from the same molecule, brought in $1.2 billion two quarters after regulators approved the drug.
Read more »
Eli Lilly raises forecast after boost in Zepbound, Mounjaro salesEli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.
Read more »